10.1 Sample Size Determination ............................................................................. 10.1.1 Preliminary Safety Cohorts and Dose Escalation (Part A) ................... 10.1.2 BMS-986226 and Nivolumab or Ipilimumab Combination Therapy Cohorts (Parts B and C) ............................................................................. 10.1.3 Combination Expansion Arms (Parts D and E) .....................................